Journal of Health Sciences & Surveillance System

Effects of Supplementation with Different Forms of Vitamin E on Liver Enzymes: A Systematic Review of Randomized Clinical Trials

Document Type : Review Articles

Authors

Tayebeh Dehghan 1
Amirhossein Asadi 1
Zahra Sohrabi 2
Marzieh Akbarzadeh 2
Kimia Leilami 1

1 Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

2 Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

https://doi.org/10.30476/jhsss.2022.96154.1639
Abstract
Background: Obesity and non-alcoholic fatty liver disease (NAFLD) are considered as the main causes of liver-associated
morbidity and mortality. Antioxidant administration was proposed as a remedy for liver problems such as steatohepatitis. This systematic review aimed to examine the effects of supplementation with various forms of Vitamin E on liver enzymes.
Methods: To find relevant articles, in our systematic review article, we searched PubMed, Scopus, Embase, Cochrane library, and Web of Science up to 20 MAY, 2021. Randomized controlled trials (RCTs) on the effects of vitamin E supplementation, in isolation or combined with other nutrients, on liver health were included. After excluding irrelevant records, 21 studies remained.
Results: According to the results of the included studies, vitamin E, especially α-Tocopherol or its co-supplementation with other antioxidants, at specific dosage could possibly have positive effects on improving liver functions and levels of Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) enzymes.
Conclusion: Vitamin E,could possibly have positive effects on improving the liver function and the levels of ALT and AST enzymes.

Highlights

Tayebeh Dehghan (Google Scholar)

Amirhossein Asadi (Google Scholar)

 

 

Keywords

Vitamin E
Alanine transaminase
Aspartate aminotransferases
Non-alcoholic fatty liver disease
Liver enzymes
  1. Fleischman MW, Budoff M, Zeb I, Li D, Foster T. NAFLD prevalence differs among hispanic subgroups: The Multi-Ethnic Study of Atherosclerosis. World journal of gastroenterology: WJG. 2014;20(17):4987. doi: 3748/wjg.v20.i17.4987. PMID: 24803810. PMCID: PMC4009531.
  2. Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology. 2019;4(5):389-98. doi: 1016/S2468-1253(19)30039-1. PMID: 30902670.
  3. Hadi HE, Vettor R, Rossato M. Vitamin E as a treatment for nonalcoholic fatty liver disease: reality or myth? Antioxidants. 2018;7(1):12. doi: 3390/antiox7010012. PMID: 29337849. PMCID: PMC5789322.
  4. Pacana T, Sanyal AJ. Vitamin E and non-alcoholic fatty liver disease. Current opinion in clinical nutrition and metabolic care. 2012;15(6):641. doi: 1097/MCO.0b013e328357f747. PMID: 23075940. PMCID: PMC4984672.
  5. Taub R. Liver regeneration: from myth to mechanism. Nature reviews Molecular cell biology. 2004;5(10):836-47. doi: 1038/nrm1489. PMID: 15459664.
  6. Osman H, Gabr O, Lotfy S, Gabr S. Serum levels of bcl-2 and cellular oxidative stress in patients with viral hepatitis. Indian journal of medical microbiology. 2007;25(4):323-9. doi: 4103/0255-0857.37333. PMID: 18087079.
  7. Reboul E, Klein A, Bietrix F, Gleize B, Malezet-Desmoulins C, Schneider M, et al. Scavenger receptor class B type I (SR-BI) is involved in vitamin E transport across the enterocyte. Journal of Biological Chemistry. 2006;281(8):4739-45. doi: 1074/jbc.M509042200. PMID: 16380385. PMCID: PMC2045115.
  8. Sutherland WH, Manning PJ, Walker RJ, De Jong SA, Ryalls AR, Berry EA. Vitamin E supplementation and plasma 8‐isoprostane and adiponectin in overweight subjects. Obesity. 2007;15(2):386-91. doi: 1038/oby.2007.546. PMID: 17299112.
  9. Rimbach G, Moehring J, Huebbe P, Lodge JK. Gene-regulatory activity of α-tocopherol. Molecules. 2010;15(3):1746-61. doi: 3390/molecules15031746. PMID: 20336011. PMCID: PMC6257188.
  10. Zingg J-M. Molecular and cellular activities of vitamin E analogues. Mini reviews in medicinal chemistry. 2007;7(5):545-60. doi: 2174/138955707780619608. PMID: 17504191.
  11. Meydani SN, Meydani M, Blumberg JB, Leka LS, Pedrosa M, Diamond R, et al. Assessment of the safety of supplementation with different amounts of vitamin E in healthy older adults. The American journal of clinical nutrition. 1998;68(2):311-8. doi: 1093/ajcn/68.2.311. PMID: 9701188.
  12. Butcher GP RJ, Walker R, Krasner N, Jackson MJ. The effect of antioxidant supplementation on a serum marker of free radical activity and abnormal serum biochemistry in alcoholic patients admitted for detoxification. Journal of hepatology. 1993;19(1):105-9. doi: 1016/s0168-8278(05)80183-7. PMID: 8301030.
  13. Cerletti C, Colucci M, Storto M, Semeraro F, Ammollo CT, Incampo F, Costanzo S, De Bartolomeo G, Portincasa P, Barone M, Di Castelnuovo A. Randomised trial of chronic supplementation with a nutraceutical mixture in subjects with non-alcoholic fatty liver disease. British journal of nutrition. 2020;123(2):190-7. PMID:  doi: 10.1017/S0007114519002484.
  14. Gan Y ML, How CB, Hay YK, Nesaretnam K, Kim-Tiu T, et al. Safety assessment of tocotrienol supplementation in subjects with metabolic syndrome: A randomised control trial. J Oil Palm Res. 2016; 28:34-43.
  15. Groenbaek K FH, Hansen M, Ring-Larsen H, Krarup HB. The effect of antioxidant supplementation on hepatitis C viral load, transaminases and oxidative status: a randomized trial among chronic hepatitis C virus-infected patients. European journal of gastroenterology & hepatology. 2006;18(9):985-9. doi: 1097/01.meg.0000231746.76136.4a. PMID: 16894312.
  16. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003 Aug 1;38(2):413-9. PMID:  doi: 10.1053/jhep.2003.50316.
  17. Shen C-L WS, Yang S, Tomison MD, Abbasi M, Hao L, et al. A 12-week evaluation of annatto tocotrienol supplementation for postmenopausal women: safety, quality of life, body composition, physical activity, and nutrient intake. BMC complementary and alternative medicine. 2018;18(1):1-10. doi: 1186/s12906-018-2263-0. PMID: 29954374. PMCID: PMC6022510.
  18. Yasuko Ota VESIPFAoRMiH-IP N, 2004, Elsevier Inc., Nutrition Volume 20, Number 4, 2004.
  19. Suzanne May Quinn Tan T-RVEfPOTaIEiDaDNAPPICT N, 10, 1315, 2018. doi: 3390/nu10091315. PMID: 30227659. PMCID: PMC6164742.
  20. MAKOTO IKEDA Soaposdadsd TJEM, 2004, 203,353-357, 2004. doi: 1620/tjem.203.353. PMID: 15297742.
  21. Jyotsna A. Patil EoVESoBPiPSoGGoWMI IJCBA-J, 2012. PMID: 23543683 doi: 1007/s12291-012-0207-x. PMCID: PMC3358367.
  22. Saeian K, Bajaj JS, Franco J, Knox JF, Daniel J, Peine C, McKee D, Varma RR, Ho S, Midwest Hepatitis Study Group. High‐dose vitamin E supplementation does not diminish ribavirin‐associated haemolysis in hepatitis C treatment with combination standard α‐interferon and ribavirin. Alimentary pharmacology & therapeutics. 2004;20(10):1189-93. PMID: 15569122. doi: 1111/j.1365-2036.2004.02260.x.
  23. Hashemian Z, Hashemi A, Fateminasab M. The Benefits of vitamin E on liver function and the hemopoietic System in thalassemia Patients. Iranian journal of pediatric hematology and oncology. 2012;2(4):153. PMID: 24575256.
  24. Clerici C, Castellani D, Russo G, Fiorucci S, Sabatino G, Giuliano V, Gentili G, Morelli O, Raffo P, Baldoni M, Morelli A. Treatment with all-trans retinoic acid plus tamoxifen and vitamin E in advanced hepatocellular carcinoma. Anticancer research. 2004 Mar 1;24(2C):1255-60. PMID: 15154656.
  25. Golnaz Ekhlasi DsaVEshfeinfldAr d-b, placebo-controlled trial , J Res Med Sci. 2016; 21: 106. doi: 4103/1735-1995.193178. PMID: 28250783. PMCID: PMC5322689.
  26. Herbay AV SW, Niederau C, Sies H. Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study. Free radical research. 1997;27(6):599-605. doi: 3109/10715769709097863. PMID: 9455695.
  27. Pervez MA KD, Slehria AUR, Ijaz A. Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled trial. Complementary Therapies in Medicine. 2020; 52:102494. doi: 1016/j.ctim.2020.102494. PMID: 32951743.
  28. Marotta F, Yoshida C, Barreto R, Naito Y, Packer L. Oxidative‐inflammatory damage in cirrhosis: effect of vitamin E and a fermented papaya preparation. Journal of gastroenterology and hepatology. 2007;22(5):697-703.PMID:  doi: 10.1111/j.1440-1746.2007.04937.x.
  29. Han Y SJ-P, Ma A-L, Xu Y, Ding X-D, Fan J-G. Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose. Clinical drug investigation. 2014;34(1):1-7. doi: 1007/s40261-013-0136-3. PMID: 24081374.
  30. Meydani SN MM, Blumberg JB, Leka LS, Pedrosa M, Diamond R, et al. Assessment of the safety of supplementation with different amounts of vitamin E in healthy older adults. The American journal of clinical nutrition. 1998;68(2):311-8. doi: 1093/ajcn/68.2.311. PMID: 9701188.
  31. Billich N, Maugeri I, Calligaro L, Truby H, Davidson ZE. Weight management interventions that include dietary components for young people with chronic health care needs: A systematic review. Nutrition and Dietetics. 2022;79(1):94-109. doi: 1111/1747-0080.12698. PMID: 34369055.
  32. Sebastiani G, Saeed S, Lebouche B, de Pokomandy A, Szabo J, Haraoui L-P, et al. Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients. Aids. 2020;34(2):237-44. doi: 1097/QAD.0000000000002412. PMID: 31651429.
  33. Bernal-Reyes R, Escudero RB. Treatment of non-alcoholic steatohepatitis (NASH). A comparative study of ursodeoxycholic acid and alpha-tocopherol. A preliminary report. Revista de gastroenterologia de Mexico. 2002;67(2):70-5. PMID: 12214337.
  34. Pervez MA, Khan DA, Ijaz A, Khan S. Effects of delta-tocotrienol supplementation on liver enzymes, inflammation, oxidative stress and hepatic steatosis in patients with nonalcoholic fatty liver disease. The Turkish Journal of Gastroenterology. 2018;29(2):170. doi: 5152/tjg.2018.17297. PMID: 29749323. PMCID: PMC6284694.
  35. Tan SMQ, Chiew Y, Ahmad B, Kadir KA. Tocotrienol-rich vitamin E from palm oil (tocovid) and its effects in diabetes and diabetic nephropathy: a pilot phase II clinical trial. Nutrients. 2018;10(9):1315. doi: 3390/nu10091315. PMID: 30227659. PMCID: PMC6164742.
  36. Cerletti C, Colucci M, Storto M, Semeraro F, Ammollo CT, Incampo F, et al. Randomised trial of chronic supplementation with a nutraceutical mixture in subjects with non-alcoholic fatty liver disease. British Journal of Nutrition. 2020;123(2):190-7. doi: 1017/S0007114519002484. PMID: 31554528.
  37. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. New England Journal of Medicine. 2000;342(17):1266-71. doi: 1056/NEJM200004273421707. PMID: 10781624.
  38. Tabei S, Fakher S, Djalali M, Javanbakht M, Zarei M, Derakhshanian H, et al. Effect of vitamins A, E, C and omega-3 fatty acids supplementation on the level of catalase and superoxide dismutase activities in streptozotocin-induced diabetic rats. Bratislava Medical Journal. 2015;116(2):115-8. doi: 4149/bll_2015_022. PMID: 25665478.
  39. Debbabi M, Nury T, Zarrouk A, Mekahli N, Bezine M, Sghaier R, et al. Protective effects of α-tocopherol, γ-tocopherol and oleic acid, three compounds of olive oils, and no effect of trolox, on 7-ketocholesterol-induced mitochondrial and peroxisomal dysfunction in microglial BV-2 cells. International journal of molecular sciences. 2016;17(12):1973. doi: 3390/ijms17121973. PMID: 27897980. PMCID: PMC5187773.
  40. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor‐β1 level and efficacy of α‐tocopherol in patients with non‐alcoholic steatohepatitis: a pilot study. Alimentary pharmacology & therapeutics. 2001;15(10):1667-72. doi: 1046/j.1365-2036.2001.01083.x. PMID: 11564008.
  41. Zhao L, Fang X, Marshall MR, Chung S. Regulation of obesity and metabolic complications by gamma and delta tocotrienols. Molecules. 2016;21(3):344. doi: 3390/molecules21030344. PMID: 26978344. PMCID: PMC6274282.
  42. Muid S, Hamid Z, Nawawi H. Tocotrienol rich fraction supplement reduces oxidative stress in non familial hypercholesterolaemia: beyond the lipid lowering capability. International Food Research Journal. 2018;25(4).
  43. Wong SK, Kamisah Y, Mohamed N, Muhammad N, Masbah N, Mohd Fahami NA, et al. Potential role of tocotrienols on non-communicable diseases: a review of current evidence. Nutrients. 2020;12(1):259. doi: 3390/nu12010259. PMID: 31963885. PMCID: PMC7019837.
  44. Herbay AV, Stahl W, Niederau C, Sies H. Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study. Free radical research. 1997;27(6):599-605. doi: 3109/10715769709097863. PMID: 9455695.
  45. Kamkwalala AR, Garg A, Roy U, Matthews A, Castillo-Mancilla J, Lake JE, et al. Current Considerations for Clinical Management and Care of People with HIV: Findings from the 11th Annual International HIV and Aging Workshop. AIDS research and human retroviruses. 2021;37(11):807-20. doi: 1089/AID.2021.0059. PMID: 34405689. PMCID: PMC8817696.

 

 

Journal of Health Sciences & Surveillance System
Volume 12, Issue 2
Spring 2024
Pages 117-124

Home

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us

Forms